Case report {#sec1}
===========

A 38-year-old man with a history of type 2 diabetes mellitus was admitted to 108 Military Central Hospital in Vietnam with a 2-day history of fatigue, cough, sputum, myalgia, fever and shortness of breath.

On admission, vital signs revealed a temperature of 39.5°C, heart rate 110 beats/minute, blood pressure 60/40 mmHg, respiratory rate 28 breaths/minute and oxygen saturation 94% with 15 L O~2~/minute via a mask with oxygen reservoir bag.

On physical examination, he was somnolent and disorientated to place, time and situation. His skin was pale. The lungs showed bibasilar rales. Another systemic examination was normal.

The laboratory test revealed a white blood cell count of 17 × 10^6^/L with neutrophils of 91%, procalcitonin of 1.83 ng/mL, glucose of 52 mmol/L. Arterial blood gas showed a pH of 7.42, Pa[co]{.smallcaps}~2~ of 20 mmHg, Pa[o]{.smallcaps}~2~ of 68 mmHg, HCO~3~^--^ of 13 mmol/L and lactate of 3.1 mmol/L. The other laboratory tests were unremarkable.

Chest radiography and CT scan revealed the bilateral lower lobe infiltration and consolidations. Two sets of blood cultures of samples and sputum culture were taken into blood agar and MacConkey agar after 24 hours of incubation at 35°C with 5% CO~2~.

Broad-spectrum antibiotic therapy was initiated with meropenem 3 g/day and ciprofloxacin 800 mg/day empirically combined with intravenously administered fluid therapy, noradrenaline and insulin.

The result of blood cultures was negative, but sputum cultures were positive for *Cedecea lapagei*. Species identification was performed using Vitek MS (bioMérieux, Marcy l'Étoile, France). The antibiotic was kept the same for 8 days, according to antimicrobial susceptibility ([Table 1](#tbl1){ref-type="table"}).Table 1Antimicrobial susceptibilities of *Cedecea lapagei* isolate obtained from 38-year-old manTable 1AntibioticMIC (μg/mL)InterpretationPiperacillin16IntermittentPiperacillin/tazobactam≤4SensitiveCeftazidime≤1SensitiveCeftriaxone≤1SensitiveCefazolin≤4SensitiveCefoxitin≤4SensitiveAztreonam≤1SensitiveImipenem≤0.25SensitiveMeropenem≤0.25SensitiveAmikacin≤2SensitiveGentamicin≤1SensitiveTobramycin≤1SensitiveLevofloxacin1SensitiveCiprofloxacin1SensitiveTrimethoprim/sulfamethoxazole≥320Resistant

On hospital day 8, he had no fever. Sputum culture was negative. Antibiotic was stopped, and he was discharged.

Discussion {#sec2}
==========

*Cedecea* is a genus of extremely rare bacteria of the family *Enterobacteriaceae*. Five species have been identified, including *Cedecea davisae*, *Cedecea lapagei* and *Cedecea neteri* and two unnamed species \[[@bib1],[@bib2]\]. *Cedecea lapagei* was recognized as a human pathogen in 2006 \[[@bib3]\].

After searching the PubMed database limited to human studies, a total of 11 cases have been identified, including four cases of pneumonia. Our patient is the fifth case of *C. lapagei* pneumonia and the first case in Vietnam.

The first report of *C. lapagei* pneumonia in a 34-year-old individual was successfully treated with tigecycline and vancomycin \[[@bib4]\]. The second case was a 76-year-old man with acute respiratory failure in Korea and was treated with cefpodoxime \[[@bib5]\]. Two cases of sepsis with *C. lapagei* nosocomial pneumonia in infants have also been reported \[[@bib6],[@bib7]\].

*Cedecea lapagei* was sensitive to ampicillin/sulbactam, tigecycline, gentamicin and tobramycin, and was resistant to multiple antibiotics, including amikacin, aztreonam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, imipenem, meropenem, moxifloxacin, nitrofurantoin and colistin \[[@bib4],[@bib7]\].

This is the first case report of pneumonia due to *C. lapagei* in an immunocompromised individual with diabetes mellitus in Vietnam. However, a significant limitation in our report is the lack of pathogen identification by 16S rRNA gene sequencing because this technique is not available in our hospital.

In conclusion, *C. lapagei* may be a newly emerging pathogen of pneumonia in humans.
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